• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GeNeuro, Servier partner for multiple sclerosis

GeNeuro, Servier partner for multiple sclerosis

December 3, 2014
CenterWatch Staff

GeNeuro, a Switzerland-based developer of new therapies for neurology and autoimmune disorders, has entered into a strategic partnership with Servier, an independent French pharmaceutical company, to develop and market GNbAC1 in multiple sclerosis (MS). As the first drug addressing a causal factor of the disease, GNbAC1 has the potential to radically change the way MS patients are treated.

GNbAC1, a humanized monoclonal antibody, targets MSRV-Env, the envelope protein of MS associated retrovirus, a member of the HERV-W family, the expression of which is usually silent but reactivated and expressed in MS lesions from an early stage in the disease. This protein has been shown to be both pro-inflammatory and an inhibitor of remyelination, the two major drivers of MS pathophysiology.

By targeting MSRV-Env, GeNeuro expects to bring to patients a safe, effective treatment that can halt progression of both relapsing-remitting and progressive forms of the disease without hampering the patient’s immune system. GNbAC1 has successfully completed phase IIa, demonstrating an optimal safety profile and encouraging signs of efficacy on a first small cohort of patients.

“GNbAC1’s original mode of action proposes a true innovation in the field of MS,” said professor Hans-Peter Hartung, chairman of the department of neurology of the University Hospital Düsseldorf and chairman of GeNeuro’s advisory board.

GeNeuro will be responsible for the development of GNbAC1 until completion of phase IIb, after which Servier can exercise the option to license the product for all markets excluding the U.S. and Japan. Financial considerations include the payment by Servier to GeNeuro of $47 million to finance the completion of phase IIb. Subsequent to exercising the option agreement, Servier will cover the costs of the phase III global development program and pay GeNeuro up to $408 million in future development and sales milestones, as well as royalties on future sales. Servier also will have the option to take an equity stake in GeNeuro as a minority shareholder in the next 12 months.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing